Empower Clinics Subsidiary Selected To Provide Diabetes Management Solutions For British Columbia’s First Nations Communities

Rhea-AI Summary

Empower Clinics has secured a contract with the British Columbia First Nations Health Authority (FNHA) to distribute diabetic testing products across First Nations communities. The partnership involves supplying MediSure's Multi-User Glucose Meter and related products from September 1, 2021 to August 31, 2023. With diabetes rates significantly higher in First Nations populations, this initiative aims to enhance diabetic management and healthcare accessibility. Empower seeks to establish itself as a leading provider of diabetic management devices in Canada.

Positive

• Secured a contract with FNHA to supply diabetic testing products, enhancing market reach.
• MediSure's proprietary products cater to a high-need demographic, potentially boosting sales.
• Partnership aligns with Empower's mission to improve healthcare accessibility for First Nations communities.

Negative

• Dependence on a contract with FNHA may pose risks if contract renewals or expansions are not secured.

Medisure Canada Signs Contract to Distribute Testing Products Across BC's First Nations Communities

VANCOUVER, BC / ACCESSWIRE / October 14, 2021 / EMPOWER CLINICS INC. (CBDT:CSE) (8EC: Frankfurt) (EPWCF:OTCQB) ("Empower" or the "Company") an integrated healthcare company serving patients through medical centers, telemedicine platforms, a medical device company, and a high complexity medical diagnostics laboratory processing COVID-19 specimens and developing a variety of direct to consumer testing protocols- is excited to announce that via a competitive process, we have been awarded a contract with the British Columbia First Nations Health Authority (FNHA) to provide diabetic testing products for communities supported by the FNHA.

Under the contract, MediSure Canada - a wholly owned subsidiary of Empower Clinics - will supply the FNHA with its proprietary MediSure Multi-User Glucose Meter, Test Strips, and Control Solution for the FNHA effective Sept. 1, 2021, to Aug. 31, 2023.

Diabetes Canada cites the rate of First Nations with diabetes living on reserve at 17 per cent and 12 per cent for those residing off reserve. This is compared to only five per cent among the general population. Through collaboration with the FNHA's community delivery program, MediSure is fulfilling its mission of providing affordable, high-quality diabetic management products to all Canadians. In conjunction with other contracts, MediSure is forging ahead on its path to become the preferred Canadian supplier of diabetic management devices.

"As a British Columbian, I'm honoured to enter into this contract with the FNHA and assist with their communities' diabetic needs," said Steven McAuley, Chairman and CEO of Empower Clinics. "Both the FNHA and Empower are striving to push the boundaries of healthcare through partnerships and delivery options that provide accessible high quality healthcare services for better patient outcomes. This is one of many contracts we are working to secure with MediSure's industry-leading and cost-effective medical devices."

This press release is available on the Empower Clinics Verified Forum on AGORACOM for shareholder discussion, questions and engagement with management https://agoracom.com/ir/EmpowerClinics

ABOUT FIRST NATIONS HEALTH AUTHORITY

The FNHA is the health and wellness partner to over 200 diverse First Nations communities and citizens across BC. The FNHA is also a champion of culturally safe practices throughout the broader health care system. Taking a leadership role, the FNHA actively works with its health partners to embed cultural safety and humility into health service delivery and improve health outcomes for First Nations people.

ABOUT EMPOWER:

Empower is an integrated healthcare company that provides body and mind wellness for patients through its clinics, with digital and telemedicine care, and world-class medical diagnostics laboratories. Supported by an experienced leadership team, Empower is aggressively growing its clinical and digital presence across North America. Our Health & Wellness and Diagnostics & Technology business units are positioned to positively impact the integrated health of our patients, while simultaneously providing long term value for our shareholders.

ON BEHALF OF THE BOARD OF DIRECTORS:

Steven McAuley
Chief Executive Officer

CONTACTS:

Investors:

Steven McAuley CEO
s.mcauley@empowerclinics.com
604-789-2146

Investors:

Tamara Mason
Business Development & Communications
t.mason@empowerclinics.com
416-671-5617

DISCLAIMER FOR FORWARD-LOOKING STATEMENTS

This news release contains certain "forward-looking statements" or "forward-looking information" (collectively "forward looking statements") within the meaning of applicable Canadian securities laws. All statements, other than statements of historical fact, are forward-looking statements and are based on expectations, estimates and projections as at the date of this news release. Forward-looking statements can frequently be identified by words such as "plans", "continues", "expects", "projects", "intends", "believes", "anticipates", "estimates", "may", "will", "potential", "proposed" and other similar words, or information that certain events or conditions "may" or "will" occur. Forward-looking statements in this news release include, but are not limited to, statements regarding: the expected benefits to the Company and its shareholders as a result of the acquisition of Kai Medical Laboratory; the transaction terms; the expected number of clinics and patients following the closing; the future potential success of Kai Medical Laboratory, Sun Valley's franchise model; launch of new healthcare centers and the occurrence thereof; that the Company can bring healthcare to millions of Canadians; that new healthcare services can be added and that the Company will be positioned to be a market- leading service provider for complex patient requirements in 2020 and beyond. Such statements are only projections, are based on assumptions known to management at this time, and are subject to risks and uncertainties that may cause actual results, performance or developments to differ materially from those contained in the forward-looking statements, including: that Kai Medical Laboratory will successfully win any US Government RFP; that the MedX Health pilot program will be successful; that Empower will place the MedX Health teledermatology product in health centers in North America; that the Company's products may not work as expected; that the Company may not be able to expand COVID-19 testing; that legislative changes may have an adverse effect on the Company's business and product development; that the Company may not be able to obtain adequate financing to pursue its business plan; that the Company will be able to commence and/or complete build-outs and tenants improvements for Canadian clinics or Kai Medical Laboratory expansion inn 2Q 2021; that general business, economic, competitive, political and social uncertainties; failure to obtain any necessary approvals in connection with the proposed transaction; and other factors beyond the Company's control. No assurance can be given that any of the events anticipated by the forward-looking statements will occur or, if they do occur, what benefits the Company will obtain from them. Readers are cautioned not to place undue reliance on the forward-looking statements in this release, which are qualified in their entirety by these cautionary statements. The Company is under no obligation, and expressly disclaims any intention or obligation, to update or revise any forward-looking statements in this release, whether as a result of new information, future events or otherwise, except as expressly required by applicable laws.

SOURCE: Empower Clinics Inc.

View source version on accesswire.com:
https://www.accesswire.com/668109/Empower-Clinics-Subsidiary-Selected-To-Provide-Diabetes-Management-Solutions-For-British-Columbias-First-Nations-Communities

FAQ

What does the contract between Empower Clinics and FNHA involve?

Empower Clinics has contracted to supply diabetic testing products, including MediSure glucose meters and test strips, to First Nations communities through FNHA.

How long is the contract with FNHA for Empower Clinics?

The contract is effective from September 1, 2021, to August 31, 2023.

What is the significance of the diabetes statistics presented in the press release?

The press release highlights that diabetes rates in First Nations communities are significantly higher than the general population, emphasizing the need for improved diabetic management.

What products will Empower Clinics supply under the FNHA contract?

Empower Clinics will supply its MediSure Multi-User Glucose Meter, test strips, and control solution as part of the contract.

What are the growth prospects for Empower Clinics after this contract?

The contract positions Empower Clinics to increase its market presence in diabetic management, potentially leading to further contracts and growth opportunities.